

Key Sanochemia Group Data

in T€

	Q1	Q1	Change as %	2008/09	2007/08
	2009/10	2008/09		2008/09	2007/08
	Oct.09-Dec.09	Oct.08-Dec.08	Oct.08-Sep.09	Oct.07-Sep.08	
Sales revenues	6,544	5,950	10 %	29,527	29,531
Sales&Marketing (Human Pharmaceuticals)	2,906	4,097	-29 %	17,033	14,787
Production	3,502	1,820	92 %	12,323	12,605
R&D	136	33	312 %	173	2,139
Reconciliation	0	0		-2	0
EBITDA	1,252	-1,810	-	34	3,667
Depreciation / amortisation	-1,100	-1,225	10 %	-4,672	-4,892
EBIT	152	-3,035	-	-4,638	-1,225
Sales&Marketing (Human Pharmaceuticals)	-70	538	-	1,714	2,223
Production	861	-1,940	-	-1,722	-321
R&D	-296	-468	37 %	-1,303	-258
Reconciliation	-343	-1,165	71 %	-3,327	-2,869
Financial result	-110	20	-	-6,196	-2,799
Pre-tax profit / loss	42	-3,015	-	-10,834	-4,024
Net profit / loss	45	-3,017	-	-10,765	-3,709
Earnings / losses per share	0.01	-0.29	-	-1.04	-0.34

	Q1	Q1	Change as %	2008/09	2007/08
	2009/10	2008/09		2008/09	2007/08
	31.12.2009	31.12.2008	30.09.2009	30.09.2008	
Balance sheet total	79,164	83,860	-6 %	81,700	88,868
Tangible assets	28,681	17,740	62 %	29,043	17,799
Intangible assets	21,861	21,719	1 %	21,991	21,956
Shareholders' equity	44,251	51,551	-14 %	44,233	54,109
Equity ratio	55.9%	61.5%	-9 %	54.1%	60.9%

IFRS Cash flow

	Q1	Q1	Change as %	2008/09	2007/08
	2009/10	2008/09		2008/09	2007/08
	Oct.09-Dec.09	Oct.08-Dec.08	Oct.08-Sep.09	Oct.07-Sep.08	
Cash flow from operating activities	1,353	-2,588		-3,593	-5,039
Cash flow from investment activity	-590	-342		-9,390	-3,375
Cash flow from financing activity	-449	-594		5,016	-1,618

Some minor changes may be due to rounding cumulative figures.
Due to the application of new IFRS guidelines, it was necessary to restate the figure of the previous year.